P. Galván

150P Validation of a genomic assay in early-stage HER2+ breast cancer (BC) treated with trastuzumab and pertuzumab (HP): A correlative analysis from PHERGain phase II trial

Antonio Llombart‐Cussac, José Manuel Pérez-García, L. Pare Brunet, G. Villacampa Javierre et autres

es, ch, gb, it, us (code pays fourni par la source)

HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis

R. Schiff, V. Guarneri, C.M. Perou, P.F. Conte et autres

Background: HER2-positive (HER2+) breast cancer (BC) comprises all the four PAM50 molecular subtypes. Among these, the HER2-Enriched (HER2-E) appear to be associated with higher pathological complete response (pCR) rates following anti-HER2-based regimens. Here, we present a meta-analysis to validate the association of …

us (code pays fourni par la source)

HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

A. Forero, María Ignacia Wehbi Vidal, P. Galván, A Llombart-Cussac et autres

Background: Identification of HER2-positive breast cancers with high anti-HER2 sensitivity could help de-escalate chemotherapy. Here, we tested a clinically applicable RNA-based assay that combines ERBB2 and the HER2-enriched (HER2-E) intrinsic subtype in HER2-positive disease treated with dual HER2-blockade without chemotherapy. Methods: A …

us (code pays fourni par la source)